论文部分内容阅读
国药股份(600511)未来的业绩有望保持持续快速增长。银根紧缩给整个医药流通业带来压力,国药股份也不能幸免,但是宏观和中观环境进一步推动行业向国控及其子公司这样的优势企业集中。公司在麻药、新特药调拨、纯销、物流已积累的领先优势,仍是医药流通业最好的投资标的。
Sinopharm shares (600511) the future performance is expected to maintain sustained and rapid growth. The monetary tightening has put pressure on the pharmaceutical distribution industry as a whole. Sinopharm shares can not be spared. However, macroeconomic and intermediate environment further promote the industry’s concentration on such dominant enterprises as Sinosure and its subsidiaries. Companies in the narcotics, the new special medicine allocation, pure sales, logistics has accumulated the leading edge, is still the best medicine circulation investment target.